U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06837142) titled 'A Drug-drug Interaction Study with TS-172 in Healthy Adult Male Subjects' on Feb. 16.
Brief Summary: An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male subjects on their pharmacokinetics, safety and tolerability
Study Start Date: March 13
Study Type: INTERVENTIONAL
Condition:
Healthy Male Subjects
Intervention:
DRUG: Triazolam and TS-172
Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administra...